ReoPro abciximab GPIIb/IIIa platelet inhibitor: Phase III data; marketed to reduce acute ischemic cardiac complications in patients undergoing percutaneous coro

CNTO presented six-month follow-up data showing a sustained long-term benefit in its 2,399-patient EPISTENT Phase III trial comparing ReoPro plus stents or ReoPro plus angioplasty to stent placement alone. Positive results from the 30-day primary end point of the trial were published last month (see BioCentury, July 13). The six-month data were presented at the European Society of Cardiology meeting in Vienna. ...